Fatty liver disease
Reading File
Finding Sources
Searching PubMed
"nonalcoholic fatty liver disease" OR "MASLD" AND treatment
Searching the Web
MASLD NAFLD fatty liver disease 2025 guidelines treatment
Reading File
Reading File
Reading File
Loading Image
Now I have comprehensive information to provide a thorough answer. Let me compile everything:
Fatty Liver Disease (MASLD / NAFLD)
Terminology Update (2023-2026)
The field has moved away from the term NAFLD (non-alcoholic fatty liver disease). The updated nomenclature now groups conditions under Steatotic Liver Disease (SLD):
- MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) - replaces NAFLD
- MASH (Metabolic dysfunction-Associated Steatohepatitis) - replaces NASH
- MetALD - a new subcategory for MASLD patients with moderate alcohol use
- ALD (Alcohol-associated Liver Disease) remains separate
The 2024 European guidelines and 2025 AGA clinical care pathway both use this framework.
What Is It?
Fatty liver disease is the accumulation of fat (primarily triglycerides) in hepatocytes, affecting ≥5% of liver cells on histology or imaging. It is the most prevalent chronic liver disease globally, with a prevalence of roughly 25% worldwide.
Disease Spectrum
The spectrum ranges from simple steatosis to cirrhosis:
| Stage | Features |
|---|---|
| MASLD (steatosis only) | Fat accumulation, no significant injury; 79-90% of NAFLD |
| MASH (steatohepatitis) | Steatosis + ballooned hepatocytes + inflammation; 10-30% |
| Fibrosis F1-F3 | Progressive scarring; 10-40% of MASH progress here |
| Cirrhosis (F4) | End-stage, irreversible; ~20% are "rapid progressors" |
Key point: Fibrosis stage (not inflammation) is the primary predictor of clinical outcomes and mortality.
Pathogenesis
The central driver is insulin resistance, typically in the setting of obesity and metabolic syndrome:
- Insulin resistance - increases adipose tissue lipolysis, flooding the liver with free fatty acids (FFAs)
- Reduced adiponectin - impairs FFA oxidation in skeletal muscle, increases hepatic FFA uptake
- De novo lipogenesis - liver synthesizes more fat
- Lipotoxicity - accumulated lipids activate:
- ER stress
- Mitochondrial dysfunction
- Lysosomal dysfunction
- Reactive oxygen species (ROS) production
- Inflammasome activation (IL-1 release)
- Hepatocyte injury - ballooned hepatocytes produce sonic hedgehog, which activates hepatic stellate cells
- Fibrogenesis - stellate cell activation causes collagen deposition
- Gut dysbiosis - alterations in gut microbiome and bile acid signaling further promote inflammation
(Robbins & Kumar Basic Pathology; Yamada's Textbook of Gastroenterology)
Risk Factors / Associated Conditions
- Type 2 diabetes (or family history)
- Obesity, especially central/abdominal obesity
- Dyslipidemia (high triglycerides, low HDL, high LDL)
- Hypertension
- Metabolic syndrome
- Genetic factors: PNPLA3 rs738409 C>G polymorphism increases HCC risk
Clinical Features
- Most patients are asymptomatic - MASLD is the most common cause of incidentally elevated serum transaminases
- AST:ALT ratio < 1 (contrast with alcoholic liver disease where ratio is typically >2)
- When symptomatic: fatigue, malaise, right upper quadrant discomfort
- Advanced disease: features of chronic liver disease (jaundice, ascites, varices)
- Cardiovascular disease is the leading cause of death in MASLD (shared risk factors)
- In patients with MASH/cirrhosis, liver-related mortality exceeds cardiovascular mortality
Diagnosis
- Imaging (ultrasound, MRI, CT) can detect steatosis but cannot reliably grade inflammation or fibrosis
- Liver biopsy remains the gold standard for:
- Confirming MASH diagnosis
- Assessing fibrosis stage
- Distinguishing MASLD from other liver diseases
- Resolving discrepancies between non-invasive tests
- Non-invasive tests: FIB-4 score, liver stiffness measurement (elastography), MRI-PDFF for steatosis quantification
- The 2026 Japanese guidelines and 2024 European guidelines both confirm biopsy is NOT routinely required for simple steatosis diagnosis, but is essential for "at-risk MASH" assessment
Complications
- Cirrhosis - the endpoint of progressive fibrosis
- Hepatocellular carcinoma (HCC) - NAFLD/MASLD is the 3rd most common cause of HCC; incidence in MASLD-cirrhosis is ~10.9 per 1,000 person-years. As hepatitis C is successfully treated, MASLD is projected to become the leading cause of HCC in the US
- Cardiovascular disease - independent risk factor
- Pediatric MASLD - increasingly prevalent; histologically distinct (portal-predominant inflammation and fibrosis, mononuclear rather than neutrophilic infiltrates)
Treatment
Lifestyle (First-Line, Most Effective)
- ≥5% body weight loss: improves steatosis, ballooning, and inflammation
- 5-10% loss: reduces inflammation
- ≥10% loss: can reverse fibrosis
- Exercise and dietary modification are the cornerstones
- Bariatric surgery for eligible patients - proven to improve MASH histology
Pharmacotherapy (Recent Approvals)
| Drug | Mechanism | Status |
|---|---|---|
| Resmetirom (Rezdiffra) | Selective thyroid hormone receptor-β agonist | FDA-approved (2024) - first approved drug for MASH with fibrosis |
| Semaglutide (GLP-1 RA) | GLP-1 receptor agonist | AASLD Nov 2025 update recommends for MASH; strong evidence for fibrosis regression |
| Other GLP-1/GIP agonists | Incretin mimetics | In trials |
| FXR agonists, ACC inhibitors, ASK1 inhibitors | Various metabolic targets | Phase II/III trials |
Recent evidence update: A 2025 network meta-analysis (PMID 39903735) comparing pharmacological therapies for MASH found significant differences in fibrosis regression and MASH resolution rates across drug classes. A 2024 systematic review (PMID 39187533) confirmed resmetirom's efficacy and safety. The AASLD also issued a November 2025 guidance specifically on semaglutide for MASH.
Alcohol
The 2024 European guidelines recommend no alcohol intake in MASLD patients (previously, light drinking was considered acceptable).
Cardiovascular Risk Management
Given CVD is the top cause of death in MASLD, management of hypertension, dyslipidemia, and diabetes is an integral part of care - not just liver-focused therapy.
Summary
MASLD is a spectrum from simple steatosis to cirrhosis, driven by insulin resistance and metabolic dysfunction. Fibrosis stage determines prognosis. Weight loss remains the cornerstone of therapy, but the field now has its first FDA-approved drug (resmetirom) and strong evidence for semaglutide in MASH. Early identification of patients at risk for advanced fibrosis using non-invasive tools is the key clinical priority.
- Robbins & Kumar Basic Pathology, p. 1910-1926
- Yamada's Textbook of Gastroenterology, 7th ed., p. 2230
- 2024 European MASLD Clinical Practice Guidelines
- AASLD 2025 Practice Guidance (semaglutide update)
For biochemistry seminar PPT
Asking for Preferences
MBBS 1st year
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your PPT is ready! Download it here:
Fatty Liver Disease MBBS
Presentation · PPTX
What's inside (15 slides)
| # | Slide | Content |
|---|---|---|
| 1 | Title Slide | Navy/teal design with amber accents |
| 2 | Seminar Outline | 10-topic overview with numbered chips |
| 3 | Definition | Key definition card + 3 fact boxes (prevalence, ALT/AST, reversibility) |
| 4 | Types of Fatty Liver | SLD umbrella with MASLD / MetALD / ALD / Other categorized in cards |
| 5 | Normal Lipid Metabolism | Hepatocyte flow diagram (inputs → hepatocyte → outputs) |
| 6 | Pathogenesis: Two-Hit Model | Hit 1 (steatosis) vs Hit 2 (inflammation) side-by-side boxes |
| 7 | Biochemical Mechanisms | 4-card grid: Insulin resistance, Lipid accumulation, Oxidative stress, Inflammation |
| 8 | Risk Factors | 6-card grid covering obesity, T2DM, dyslipidemia, HTN, genetics, alcohol |
| 9 | Disease Spectrum & Progression | Steatosis → MASH → F1-F2 → F3 → Cirrhosis with % progression rates |
| 10 | Clinical Features & Diagnosis | Two-column layout: symptoms vs diagnostic tools |
| 11 | Complications | Cirrhosis, HCC, CVD, metabolic syndrome - 4 cards |
| 12 | Treatment & Management | 3-tier layout: lifestyle → pharmacotherapy (resmetirom, semaglutide) → bariatric surgery |
| 13 | High-Yield Biochemistry Points | 8 exam-focused facts (SREBP-1c, CPT-1, VLDL, NLRP3, TGF-β, etc.) |
| 14 | Summary | Dark slide with 8 key takeaways |
| 15 | Thank You / References | Textbook + guideline citations |
Color scheme: Navy dominant, teal headers, amber highlights - designed for a professional biochemistry seminar look.
This is a shared conversation. Sign in to Orris to start your own chat.